Flutemetamol (18F)

• A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised
  2022-501644-15-00 Phase II 11 countries Biogen Idec Research Limited
• Locating microclots with PET in post-COVID syndrome Pending
  2025-522348-42-00 Phase I/II 1 country Amsterdam UMC Stichting
• An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518006-40-00 Phase III 6 countries F. Hoffmann-La Roche AG
• Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and of glucose metabolism with 18F-FDG PET in individuals enrolled… Recruiting
  2024-519961-23-00 Phase IV 1 country Barcelonabeta Brain Research Center
• A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime… Recruiting
  2023-509807-34-00 Phase II 3 countries Acumen Pharmaceuticals Inc.
• A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518008-33-00 Phase III 7 countries F. Hoffmann-La Roche AG
• MRI contrast agent in the spinal canal to investigate transportation of the cerebrospinal fluid in the brain. Recruiting
  2024-520146-33-00 Phase I/II 1 country Region Vaesterbotten
• Amyloid pathology in cognitively normal elderly subjects (PreclinAD) Recruiting
  2024-518559-41-01 Phase II 1 country Amsterdam UMC Stichting
• Patient- and care-related benefits of amyloid PET imaging (ENABLE) Recruiting
  2023-503705-10-00 Phase IV 1 country Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
• Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study) Recruiting
  2023-510508-31-01 Phase II 1 country Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau
• The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders Recruiting
  2024-511842-38-00 Phase II 1 country Region Skane
• A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim… Ended
  2023-506183-13-00 Phase II 6 countries F. Hoffmann-La Roche AG
• A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended
  2022-501644-15-01 Phase II 11 countries Biogen Idec Research Limited
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 Phase II 8 countries Glaxosmithkline Research & Development Limited
• Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl… Ended
  2024-517971-19-01 Phase II 1 country Fondazione Toscana Gabriele Monasterio

Showing 1–15 of 15 trials